Licensing
In an industry some accuse of stagnating, the ongoing rapid growth of licensing is a shining example of continuing clinical and business innovation and leadership. The rise of licensing – now more than half of major companies’ new product launches and much of their pipeline – has led to increased competition, escalated deal terms and eroding returns. Oliver Wyman helps pharmaceutical and biotech companies face these challenges to maximize the enormous benefits licensing can offer.
Over the past decade, our unique approach and proprietary models have generated superior investment returns for clients ranging from multi-nationals to research-based start-ups. We have developed a leading edge licensing forecasting and modeling platform while also offering insight on the capabilities that are key to successful licensing partnerships and alliances.
Our licensing expertise centers on a depth of experience in:
- Licensing strategy
- Economic attractiveness of various therapeutic areas and disease/conditions
- In-licensor competitiveness, partnering strategy
- 3rd party financing, risk business case
- Deal support
- Compound forecasting
- Risk quantification
- Negotiation modeling and support
- Strategic diligence
- Process management
- Alliance management
- Linking licensing to alliance roles
- Governance structuring and on-boarding
- Rigorous project management
- Risk Management
- Compound, therapeutic area and portfolio risk assessments
- Risk-management driven licensing strategy development
Experts
David Campbell, Andrew Chadwick-Jones, Mark Mozeson
